<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T2" orientation="portrait" position="float">
 <label>Table 2.</label>
 <caption>
  <p>Management of Patients with Preexisting Endocrine Conditions who are Affected with COVID-19</p>
 </caption>
 <table frame="vsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="1" colspan="1">Endocrine Condition</th>
    <th rowspan="1" colspan="1">Management</th>
    <th rowspan="1" colspan="1"/>
    <th rowspan="1" colspan="1"/>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="1" colspan="1">Diabetes insipidus</td>
    <td rowspan="1" colspan="1">Titrate the dose of desmopressin according to serum sodium, and osmolality. Convert to parenteral form (IV/IM) if intranasal route is not feasible [
     <xref rid="CIT0052" ref-type="bibr">52</xref>] 
     <break/> Desmopressin dose equivalents [
     <xref rid="CIT0138" ref-type="bibr">138</xref>]
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1">
     <bold>Tablets</bold>
    </td>
    <td rowspan="1" colspan="1">
     <bold>Spray</bold>
    </td>
    <td rowspan="1" colspan="1">
     <bold>Injections</bold>
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1">
     <bold>100 µg</bold>
    </td>
    <td rowspan="1" colspan="1">2.5 µg</td>
    <td rowspan="1" colspan="1">NA</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1">
     <bold>200 µg</bold>
    </td>
    <td rowspan="1" colspan="1">5.0 µg</td>
    <td rowspan="1" colspan="1">&lt;0.5 µg</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1">
     <bold>400 µg</bold>
    </td>
    <td rowspan="1" colspan="1">10.0 µg</td>
    <td rowspan="1" colspan="1">&lt;1.0 µg</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Hyperprolactinemia</td>
    <td rowspan="1" colspan="1">Bromocriptine: may need dose adjustment because of interactions between lopinavir/ritonavir, which increase bromocriptine levels [
     <xref rid="CIT0055" ref-type="bibr">55</xref>] 
     <break/> Cabergoline: dose adjustment is not required
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">GH deficiency</td>
    <td rowspan="1" colspan="1">Continue on the same dose of growth hormone in those with established GH deficiency [
     <xref rid="CIT0058" ref-type="bibr">58</xref>]
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Hypoadrenalism</td>
    <td rowspan="1" colspan="1">Double the morning dose of hydrocortisone and continue 20 mg 4 times daily, or give doubled usual hydrocortisone dose (“sick day rule”), depending on the infection severity and patient characteristics [
     <xref rid="CIT0064" ref-type="bibr">64</xref>] 
     <break/> During an adrenal crisis, IM or IV hydrocortisone 100 mg stat followed by 200 mg over 24-hour infusion [
     <xref rid="CIT0066" ref-type="bibr">66</xref>] 
     <break/> Patients with primary hypoadrenalism do not require increasing fludrocortisone dose [
     <xref rid="CIT0065" ref-type="bibr">65</xref>] 
     <break/> Critical illness-related corticosteroid insufficiency (CIRCI): IV hydrocortisone 400 mg daily for 3 days or longer depending on the requirement [
     <xref rid="CIT0070" ref-type="bibr">70</xref>]
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Cushing’s syndrome</td>
    <td rowspan="1" colspan="1">Continue medical management in those with active disease 
     <break/> IV etomidate at a rate of 0.04 to 0.05 mg/kg/h for those with severe illness targeting a cortisol level 500-800 nmol/L [
     <xref rid="CIT0078" ref-type="bibr">78</xref>, 
     <xref rid="CIT0079" ref-type="bibr">79</xref>] 
     <break/> Anticoagulation to be considered in acute illness [
     <xref rid="CIT0075" ref-type="bibr">75</xref>]
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Pheochromocytoma/paraganglioma</td>
    <td rowspan="1" colspan="1">Treatment with initial alpha-adrenoceptor blockers followed by beta-adrenoceptor blockers depending on the blood pressure and heart rate [
     <xref rid="CIT0081" ref-type="bibr">81</xref>]
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Hypothyroidism</td>
    <td rowspan="1" colspan="1">No thyroxine dose adjustments are required</td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Hyperthyroidism</td>
    <td rowspan="1" colspan="1">Dose adjustment of antithyroid medications as usual according to the thyroid function tests. If blood tests cannot be performed, dose adjustments may be made based on thorough history and examination. 
     <break/> Short-term block and replacement therapy as an alternative [
     <xref rid="CIT0087" ref-type="bibr">87</xref>]
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Hypoparathyroidism</td>
    <td rowspan="1" colspan="1">Ensure a continuous supply of calcium supplements 
     <break/> Maintain normocalcemia as hypocalcemia increases the risk of QT prolongation with chloroquine/hydroxychloroquine and azithromycin [
     <xref rid="CIT0112" ref-type="bibr">112</xref>] 
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Vitamin D deficiency</td>
    <td rowspan="1" colspan="1">Vitamin D supplements to achieve a target level of &gt; 50 nmol/L (20 ng/mL) [
     <xref rid="CIT0130" ref-type="bibr">130</xref>] 
     <break/> During winter seasons, 2000-5000 IU daily up to 10 000 IU depending on the requirement [
     <xref rid="CIT0131" ref-type="bibr">131</xref>, 
     <xref rid="CIT0132" ref-type="bibr">132</xref>]
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Hypogonadism</td>
    <td rowspan="1" colspan="1">
     <bold>Testosterone</bold>
     <break/> Temporary discontinuation may be possible if medication is not available or changing to an alternative is possible (e.g., intramuscular injections to testosterone gel) 
     <break/>
     <bold>Estrogen</bold>
     <break/> Conversion to transdermal formulations when applicable as the thrombosis risk is lower with transdermal compared to oral estrogen
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
  </tbody>
 </table>
</table-wrap>
